August 31, 2006

ThermoDox™ Animal Studies to be Presented at 6th International Symposium on Therapeutic Ultrasound in Oxford, England

ThermoDox™ Animal Studies to be Presented at 6th International Symposium on Therapeutic Ultrasound in Oxford, England

Columbia, MD - August 31, 2006: CELSION CORPORATION (AMEX: CLN) today announced that a study treating tumors in mice with either ThermoDox combined with pulsed high intensity focused ultrasound (HIFU) or Doxil® combined with pulsed HIFU will be presented at the 6th International Symposium on Therapeutic Ultrasound in Oxford, England (30th August - 2nd September 2006). In the study, to be presented by Brad Wood, M.D., Victor Frankel, Ph.D., and Sergio Dromi, M.D., of the National Institutes of Health Clinical Center (NIH), ThermoDox (heat sensitive liposomal doxorubicin) administered in combination with pulsed HIFU, as the activating heat source, not only increased doxorubicin concentrations in the tumors but also significantly prolonged the delay in tumor growth in comparison to the combination of HIFU with Doxil a non-heat sensitive liposomal formulation of doxorubicin.

Dr. Wood noted that, "The minor temperature elevations and mechanical forces associated with pulsed HIFU exposure were able to enhance the delivery of doxorubicin from ThermoDox to the tumors and that produced a significant reduction in the growth of the tumors, compared to using the thermosensitive liposomes without HIFU, or Doxil with or without HIFU."

The study was supported, in part, under a collaborative research and development agreement between the NIH and Celsion Corporation.

Celsion is currently sponsoring a phase I dose escalation study using ThermoDox in combination with radio-frequency ablation to treat liver cancer. The study is presently underway at the National Cancer Institute, under the supervision of Dr. S. Libutti and Dr. B. Wood, and at Queen Mary Hospital, an affiliate of University of Hong Kong, in Hong Kong, under the supervision of Dr R. Poon. Celsion also has funded another ongoing phase I dose escalation study at Duke University, under the supervision of Dr K. Blackwell, for the treatment of local-regionally advanced breast cancer.

Dr. Lawrence Olanoff, Celsion's President and Chief Executive Officer, commented, "These results are very encouraging because they demonstrate significant anti-tumor efficacy of ThermoDox using a different animal model and a different heat activating source. The results go a long way to confirm our contention that cancer chemotherapeutic agents encapsulated in heat sensitive liposomes can be activated at target organ sites by a variety of different heating devices. They also reinforce our belief that the proprietary heat activated liposome in which we have encapsulated doxorubicin to produce ThermoDox could be a platform upon which we can ultimately build a range of different oncology drugs."

National Institute of Health Disclaimer: Participation in this study by the National Institute of Health, its Institutes or Centers or Clinical Centers should not be viewed as an endorsement of Celsion Corporation, its products or services.

ABOUT CELSION: Celsion Corporation, based in Columbia, Maryland, is a biotechnology company dedicated to the development and commercialization of heat activated treatment systems for cancer.

Celsion has research, license or commercialization agreements with leading institutions such as the National Institute of Health, Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, Montefiore Medical Center and Memorial Sloan-Kettering Cancer Center in New York City, Roswell Park Cancer Institute in Buffalo, New York, and Duke University. For more information on Celsion, visit our website: www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

For Further Information Contact:

Tony Deasey
Celsion Corporation
410-290-5390
tony@celsion.com

General Info: Marilynn Meek
Financial Relations Board
212-827-3773
mmeek@financialrelationsboard.com

Investor Info: Susan Garland
212-827-3775
sgarland@financialrelationsboard.com


Close window | Back to top

Copyright 2014 Celsion Corporation